Literature DB >> 30303835

Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.

Chih-Cheng Lai1, Ya-Hui Wang2, Cheng-Yi Wang3, Hao-Chien Wang4, Chong-Jen Yu4, Likwang Chen5.   

Abstract

OBJECTIVES: This study aimed to compare the effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk and outcomes of sepsis in patients with chronic obstructive pulmonary disease.
DESIGN: A retrospective study.
SETTING: Taiwan's National Health Insurance Research Database. PATIENTS: All patients with chronic obstructive pulmonary disease who received angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for more than 90 days between 2000 and 2005 were recruited for this study. Pairwise matching (1:1) of the angiotensin-converting enzyme inhibitor and angiotensin receptor blocker groups resulted in two similar subgroups with 5,959 patients in each.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was sepsis, and the secondary outcome was death. The occurrence rate of sepsis was 3.67 per 100 person-years for the patients receiving angiotensin-converting enzyme inhibitors and 2.87 per 100 person-years for those receiving angiotensin receptor blockers. In addition, the patients receiving angiotensin-converting enzyme inhibitors had a higher risk of septic shock (adjusted hazard ratio, 1.45; 95% CI, 1.26-1.67) and mortality (adjusted hazard ratio, 1.31; 95% CI, 1.22-1.40) than those receiving angiotensin receptor blockers. No matter whether the patients had prior severe exacerbation before the index date, those receiving angiotensin-converting enzyme inhibitors had a higher risk of sepsis, septic shock, and mortality than those receiving angiotensin receptor blockers (all p < 0.001).
CONCLUSIONS: Angiotensin receptor blockers were associated with lower rates of sepsis and mortality than angiotensin-converting enzyme inhibitors in the patients with chronic obstructive pulmonary disease. The similar findings were also noted in subgroup analysis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30303835     DOI: 10.1097/CCM.0000000000003475

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

1.  Angiotensin II Receptor Blockers but Not Angiotensin-Converting Enzyme Inhibitors Are Associated With a Reduced Risk of Acute Kidney Injury After Major Surgery.

Authors:  Shao-Yu Yang; Tao-Min Huang; Tai-Shuan Lai; Nai-Kuan Chou; Chun-Hao Tsao; Yi-Ping Huang; Shuei-Liong Lin; Yung-Ming Chen; Vin-Cent Wu
Journal:  Front Pharmacol       Date:  2021-04-23       Impact factor: 5.810

2.  Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19.

Authors:  Cachet Wenziger; Elani Streja; Amrita Ahluwalia; John G Rizk; Diana Tran; Leila Hashemi; Hamid Moradi
Journal:  Drugs       Date:  2021-12-16       Impact factor: 9.546

3.  Angiotensin II Receptor Blocker Associated With Less Outcome Risk in Patients With Acute Kidney Disease.

Authors:  Vin-Cent Wu; Yu-Feng Lin; Nai-Chi Teng; Shao-Yu Yang; Nai-Kuan Chou; Chun-Hao Tsao; Yung-Ming Chen; Jeff S Chueh; Likwang Chen
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

4.  The effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in critically ill patients with acute kidney injury: An observational study using the MIMIC database.

Authors:  Xu Zhu; Jing Xue; Zheng Liu; Wenjie Dai; Jingsha Xiang; Hui Xu; Qiaoling Zhou; Quan Zhou; Xinran Wei; Wenhang Chen
Journal:  Front Pharmacol       Date:  2022-08-29       Impact factor: 5.988

5.  Renin-angiotensin system antagonists and mortality due to pneumonia, influenza, and chronic lower respiratory disease in patients with hypertension.

Authors:  Heng-Xuan Cai; Chen-Chen Liang; Shan-Jie Wang; Jun-Chen Guo; Ye Wang; Bo Yu; Xue-Qin Gao; Shao-Hong Fang
Journal:  J Geriatr Cardiol       Date:  2022-07-28       Impact factor: 3.189

6.  Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists.

Authors:  Cheng-Yi Wang; You Shuei Lin; Ya-Hui Wang; Chih-Cheng Lai; Hao-Chien Wang; Likwang Chen; Chong-Jen Yu
Journal:  Aging (Albany NY)       Date:  2019-09-10       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.